Remepy Secures $36 Million to Advance AI-Driven Hybrid Drugs

Remepy, an Israeli developer of hybrid drugs combining prescription medicines with AI-driven therapeutic applications, has secured $36 million in Series A funding. The round was led by O.G. Venture Partners and M Ventures, Merck's strategic investment arm.

The company will use the proceeds to advance its pharmaceutical co-development partnerships, expand its Hybrid Drug pipeline, and fund global Phase III clinical development of Hybridopa for Parkinson's disease.

Remepy's lead program, Hybridopa, has shown promising results in Phase IIa trials, improving motor and non-motor symptoms. The company is preparing Hybridopa for global Phase III development, expected to begin in the fourth quarter of 2026.